Today: 20 May 2026
First Solar stock slides 10% on Jefferies downgrade as 2026 orders come into focus

First Solar stock slides 10% on Jefferies downgrade as 2026 orders come into focus

New York, January 7, 2026, 18:48 (EST) — After-hours

Shares of First Solar (FSLR) fell 10.3% to $241.11 on Wednesday after Jefferies downgraded the U.S. solar panel maker to “hold” from “buy” and cut its price target to $260 from $269. The brokerage cited “limited booking visibility” for 2026 and said a hoped-for “S232” tailwind — shorthand for potential Section 232 duties that can be imposed after a Commerce Department national-security investigation — could “underwhelm investor expectations,” flagging possible carve-outs for Germany and developers moving ahead of any levies. The stock opened at $254.02 and touched $239.26 at its low; volume was about 6.2 million shares. TipRanks

The downgrade lands after a strong run: First Solar has risen about 28% over the past year, Barron’s reported. The shares closed Tuesday at $268.78, about 6% below a $285.99 52-week high set on Dec. 22, MarketWatch data showed.

That rally has leaned on the idea that U.S. makers with domestic capacity could hold pricing as imports face tighter scrutiny. For traders, the swing factor is orders: new bookings and cancellations can change revenue expectations quickly.

At its third-quarter update in October, the company reported a contracted backlog of 54.5 gigawatts through 2030 and said it had booked about 2.7 GW since the prior call, according to its earnings presentation. It also said it terminated 6.6 GW of bookings tied to defaults by BP affiliates, lifting total “debookings” — cancellations of future orders — to 6.9 GW. First Solar has said a new 3.7-gigawatt U.S. factory is due to start production at the end of 2026. Q4 Investor Relations+1

Other solar names were mixed. Sunrun fell 5.1% and Canadian Solar dropped 6.3%, while Enphase and SolarEdge were little changed.

But the trade call is a moving target. Any Section 232 action could be delayed, watered down by exemptions, or pulled forward by developers trying to lock in supply — outcomes that can soften the pricing lift bulls expect.

At $241, Jefferies’ $260 target implies about 8% upside, leaving a narrower margin for surprise. Traders will watch for signs that bookings recover and for any fresh guidance on costs and factory output.

U.S. labor and inflation data are next on the calendar: the December jobs report is due Friday at 8:30 a.m. ET and December CPI follows on Jan. 13. First Solar is scheduled to report results on March 3 after the close, according to TipRanks. Traders also have the Federal Reserve’s Jan. 27-28 policy meeting in view.

Stock Market Today

  • Trump's Truth Social Withdraws Bitcoin and Bitcoin-Ethereum ETF Applications Amid Market Pressure
    May 20, 2026, 7:22 AM EDT. Trump Media & Technology Group has withdrawn its applications for Bitcoin and Bitcoin-Ethereum exchange-traded funds (ETFs), citing a strategic shift to pursue a different regulatory framework under the Investment Company Act of 1940 ('40 Act) instead of the Securities Act of 1933 ('33 Act). Yorkville America, the investment advisor, highlighted that the '40 Act allows more flexible investment strategies. This move comes amid intense fee competition in the U.S. spot Bitcoin ETF market, valued at $57.4 billion since January 2024, following Morgan Stanley's MSBT launch, which offers a low 0.14% expense ratio. The withdrawal underscores heightened competition and evolving regulatory approaches in the crypto ETF space.

Latest articles

InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested

InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested

20 May 2026
InMed Pharmaceuticals shares fell 14.4% to $1.37 in early pre-market trading Wednesday, after surging 135% Tuesday on news of an all-stock merger with Mentari Therapeutics and a planned $290 million private placement. Pre-merger InMed shareholders are expected to own about 1.51% of the combined company, which will operate as Mentari Therapeutics and focus on migraine drug development.
Micware Shares Swing Pre-Market After 26% Drop on Nasdaq Debut

Micware Shares Swing Pre-Market After 26% Drop on Nasdaq Debut

20 May 2026
Micware shares jumped 97.7% to $9.33 in premarket U.S. trading Wednesday, rebounding above last week’s $8 IPO price after closing Tuesday at $4.72. A new SEC filing showed Toyota owns 11.6% of Micware’s ordinary shares. The Japanese automotive software firm raised $22.8 million in its Nasdaq debut last week.
Dow edges up while Nasdaq falls as bond worries drag on

Futures Edge Higher Ahead of Nvidia Earnings as Wall Street Watches Key Report

20 May 2026
Nasdaq 100 futures rose 0.73% and S&P 500 futures gained 0.35% ahead of Wednesday’s open, with Nvidia set to report earnings after the close. Options markets priced in a 6.5% swing for Nvidia, equal to about $355 billion in market value. In premarket trading, Nvidia shares rose 1.84%, while Micron, Intel, and AMD also advanced. Fed minutes are due at 2:00 p.m. EDT.
Johnson & Johnson stock rises on Ottava robot FDA filing as investors scan pipeline updates
Previous Story

Johnson & Johnson stock rises on Ottava robot FDA filing as investors scan pipeline updates

Wall Street jolted by Trump buyback, home-buying moves; S&P 500 slips, Nasdaq steadied by AI
Next Story

Wall Street jolted by Trump buyback, home-buying moves; S&P 500 slips, Nasdaq steadied by AI

Go toTop